PhaseV Unveils AI/ML Tools for Clinical Trial Design at CMO Summit

PhaseV announced in a press release that it will showcase its latest AI/ML-powered capabilities for clinical trial design and analysis at the upcoming Chief Medical Officer (CMO) Summit 360° in Boston. The new tools are designed to integrate insights from previous clinical trials into future study designs, enhancing decision-making and improving patient outcomes.

The platform's Causal to Adaptive capability allows clinical teams to leverage causal machine learning-driven insights from prior trials and real-world data. This integration aims to improve planning, efficiency, and decision-making for future clinical trials. Additionally, the Clinical Trial Success Prediction tool quantifies the probability of success by analyzing historical trial data and real-world evidence, supporting more informed decision-making and reducing failure rates.

Live demonstrations of these capabilities will be conducted at the CMO Summit 360° in Boston from April 7-8, providing attendees with an opportunity to see the platform's potential in action.